@metabolon.bsky.socialWhat’s the most important unanswered question in diabetes research?
At #EASD2026, Dr. Denise Faustman shared why looking beyond blood glucose matters, and how metabolomics can help resolve the underlying biology.
▶️ Watch her perspective.
@biomedicines.bsky.social#EASD2026 came to a successful close! 👏
It was a pleasure to welcome our Editorial Board Member, Dr. Laura Marroquí Esclapez, at our booth! We greatly appreciate her support and valuable contributions & look forward to continuing our collaboration in #Biomedicines!🤝
@newsen.bsky.socialSIBIONICS and PharmaSens Discover New Frontiers in Automated Insulin Management at EASD 2026 #None #Milano #SIBIONICS #PharmaSens #EASD2026
@biomedicines.bsky.social#EASD2026 has wrapped up! 👏
It was a pleasure to meet our Guest Editor, Dr. Tomislav Bulum, at our booth! We appreciate his support and valuable contribution and we look forward to continuing our collaboration and working together! 🤝
#Conference #Biomedicines
@springermedicine.com
@sociedadseen.bsky.social📢 El 8 de octubre, revisaremos los principales avances del #EASD2026 en diabetes: tecnología en DM1 y DM2, nuevas dianas terapéuticas, enfermedad cardiorrenal, obesidad, medicina de precisión y más.
@easdnews.bsky.social🎥💙 The #EASD2026 Annual Meeting may be over, but the conversations continue.
We asked delegates why they do what they do: 60 seconds each, 1️⃣thing in common: they all want to help people.
🎬👇 Watch "Human Behind Science" & meet the people behind the research.
@diabresearch-dzd.bsky.social🔬 DZD at EASD 2026:A short photo review
Exciting research, inspiring scientific sessions, prestigious awards and many valuable conversations at the DZD booth. Thank you to everyone who visited us and helped make #EASD2026 such a special event!
📸 A short photo review
#DZD #DiabetesResearch
@springermedicine.com
@midgardfinance.com🇺🇸 $LLY #retatrutide took off 18.8% in type 2 diabetes, the most of six drugs. 🇩🇪 Boehringer's #survodutide, from 🇩🇰 $ZEAL: 9.8%, and 26% stopped for side effects. All randomised patients.
All of EASD in one post:
midgardfinance.com/blog/2026/10/04/easd-2026-roundup/
@easoobesity.bsky.socialEASO was delighted to join colleagues from EASD, ESC and EUDF and welcome EU Health Commissioner Oliver Varhelyi to launch #EUScreeningWeek in Milano at #EASD2026. View the press event: audiovisual.ec.europa.eu/en/media/vid...
Read the press release: easo.org/eu-screening...
@conscienhealth.bsky.socialAt #EASD2026 in Milan this week, a dazzling show of new data on obesity and diabetes fits a broader picture looking beyond weight outcomes to health outcomes.
HT: @elilillyandcompany.bsky.social @novonordisk.bsky.social @regeneron.com @boehringerglobal.bsky.social
conscienhealth.org/2026/10/03/e...
@easdnews.bsky.social
@idfe.bsky.social💙 What a week for our #KnowYourNumbers Mobile Unit at #EASD2026!
📍 300 health checks delivered to congress attendees and the public, supporting the launch of the first-ever #EUScreeningWeek. Making prevention more accessible and helping people understand their health numbers.
@practicaldiabetic.bsky.social#EASD2026 : Almost 10k (6 miles per day) ;)
@springermedicine.comFrom #EASD2026 - Orforglipron, an oral non-peptide #GLP1 receptor agonist may be a feasible treatment option for patients with type 2 diabetes who are at increased cardiovascular risk.
Full story 👉️ buff.ly/TRkGkce
@medpagetoday.comAdults with type 2 diabetes achieved impressive weight loss with an investigational combination agent of eloralintide plus tirzepatide (Mounjaro, Zepbound), according to a phase IIb study. @easdnews.bsky.social #EASD2026
https://www.medpagetoday.com/meetingcoverage/easd/123239
@theisn.org🌍 ISN was delighted to be at #EASD2026 in Milan represented by Maria José Soler presenting “Early combination therapy in diabetic kidney disease: Is the time to act now?”
A valuable opportunity to exchange knowledge and strengthen collaboration across specialties to advance kidney care worldwide.
